Bionovate Technologies Corp Stock Performance
| BIIO Stock | USD 0.0001 0.00 0.000003% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Bionovate Technologies are completely uncorrelated. Bionovate Technologies right now shows a risk of 0.0%. Please confirm Bionovate Technologies day typical price , to decide if Bionovate Technologies will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bionovate Technologies Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Bionovate Technologies is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:100 | Dividend Date 2020-01-09 | Last Split Date 2020-01-09 |
1 | Stock Market Today Dow, Nasdaq Sink as AI Fears Resurface Live Updates - The Wall Street Journal | 11/20/2025 |
Bionovate | Build AI portfolio with Bionovate Stock |
Bionovate Technologies Relative Risk vs. Return Landscape
If you would invest 0.01 in Bionovate Technologies Corp on October 4, 2025 and sell it today you would earn a total of 0.00 from holding Bionovate Technologies Corp or generate 0.0% return on investment over 90 days. Bionovate Technologies Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Bionovate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bionovate Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bionovate Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bionovate Technologies Corp, and traders can use it to determine the average amount a Bionovate Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BIIO |
Based on monthly moving average Bionovate Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bionovate Technologies by adding Bionovate Technologies to a well-diversified portfolio.
Bionovate Technologies Fundamentals Growth
Bionovate Stock prices reflect investors' perceptions of the future prospects and financial health of Bionovate Technologies, and Bionovate Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionovate Stock performance.
| Current Valuation | 238.3 K | ||||
| Shares Outstanding | 7.75 M | ||||
| Price To Earning | 0.05 X | ||||
| EBITDA | (45.61 K) | ||||
| Net Income | (106.54 K) | ||||
| Total Debt | 237.38 K | ||||
| Book Value Per Share | (0.07) X | ||||
| Market Capitalization | 775 | ||||
| Retained Earnings | (2.8 M) | ||||
| Working Capital | (503.21 K) |
About Bionovate Technologies Performance
By examining Bionovate Technologies' fundamental ratios, stakeholders can obtain critical insights into Bionovate Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bionovate Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 134.86 | 171.39 | |
| Return On Tangible Assets | (47.13) | (49.49) | |
| Return On Capital Employed | 0.08 | 0.09 | |
| Return On Assets | (47.13) | (49.49) | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Bionovate Technologies performance evaluation
Checking the ongoing alerts about Bionovate Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bionovate Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionovate Technologies generated a negative expected return over the last 90 days | |
| Bionovate Technologies has some characteristics of a very speculative penny stock | |
| Bionovate Technologies has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (106.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bionovate Technologies has a very weak financial position based on the latest SEC disclosures | |
| About 49.0% of the company shares are held by company insiders |
- Analyzing Bionovate Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionovate Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Bionovate Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionovate Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionovate Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionovate Technologies' stock. These opinions can provide insight into Bionovate Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionovate Technologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionovate Technologies. If investors know Bionovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionovate Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionovate Technologies is measured differently than its book value, which is the value of Bionovate that is recorded on the company's balance sheet. Investors also form their own opinion of Bionovate Technologies' value that differs from its market value or its book value, called intrinsic value, which is Bionovate Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionovate Technologies' market value can be influenced by many factors that don't directly affect Bionovate Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionovate Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionovate Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionovate Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.